Source: Kapitales ResearchHighlights

• CurveBeam AI Limited secured binding commitments for an AU$5.0 million institutional placement and unveiled a Share Purchase Plan (SPP) targeting up to AU$1.0 million.
• The company reported 80% quarter-on-quarter growth in customer receipts to AU$2.58 million, while progressing its China commercialisation strategy and robotic surgery partnerships.
• The proceeds will accelerate HiRise™ commercialisation in China, strengthen sales and marketing, fund product development, enhance supply chain capabilities and support general working capital.

Fresh Capital Strengthens Growth StrategyCurveBeam AI Limited (ASX: CVB) has announced a comprehensive capital raising to strengthen its financial position and accelerate commercial expansion. With the stock trading at a CMP of AU$0.019, up 5.55%, the company secured binding commitments for an AU$5.0 million placement while also launching a Share Purchase Plan (SPP) targeting a further AU$1.0 million.The placement comprises approximately 250.0 million new fully paid ordinary shares priced at AU$0.020 per share, representing an 11.1% premium to the last closing price of AU$0.018 on 3 July 2026 and an 8.8% discount to the five-day volume weighted average price of AU$0.02194.Directors Demonstrate Confidence Through InvestmentDirector participation formed a significant component of the raising. CEO and Director Greg Brown committed AU$300,000, while President and Director Arun Singh and Susmita Singh subscribed AU$2.05 million. Other institutional and sophisticated investors contributed AU$2.65 million, highlighting broad support for the company's long-term strategy.In addition, Arun Singh has advanced an unsecured AU$2.05 million loan to the company at an annual interest rate of 5%, providing immediate liquidity until the placement completes following shareholder approval. The loan matures on 1 October 2027 or earlier upon settlement of his placement shares.Funding to Support China Expansion and Product DevelopmentManagement intends to deploy the proceeds across several strategic priorities, including sales and marketing initiatives, HiRise™ product enhancements, supply chain expansion, preparations for the China commercial launch, and additional working capital.Eligible shareholders in Australia and New Zealand will also have the opportunity to participate through the non-underwritten SPP, allowing subscriptions of up to AU$100,000 per shareholder at AU$0.018 per share, with the company targeting approximately AU$1.0 million while retaining discretion to accept oversubscriptions.Quarterly Update Highlights Improving Commercial MomentumAlongside the capital raising, CurveBeam AI reported encouraging operational progress during the June quarter. The company secured two HiRise™ purchase orders, generated customer receipts of AU$2.58 million, representing an 80% increase from the previous quarter's AU$1.43 million, and carried AU$4.2 million of purchase orders and receivables into Q1 FY27.The business continues progressing its China strategy, having responded to regulatory feedback from China's National Medical Products Administration (NMPA). Management continues to target NMPA clearance during the second half of calendar 2026, which would trigger an AU$1.0 million milestone payment from Weiying, followed by an initial commercial order for HiRise™ systems. Additional milestone payments of AU$1.0 million and AU$2.0 million are linked to the sale of the first 10 and 50 HiRise™ systems, respectively.The company also continued validation work with leading robotic surgery platform developers while advancing FDA regulatory activities for its Bone Mineral Density software, supporting broader commercial opportunities.OutlookCurveBeam AI has significantly strengthened its near-term funding position while maintaining momentum across several commercial and regulatory milestones. The fresh capital provides additional flexibility to support the planned China launch, ongoing product innovation and operational execution. Combined with improving customer receipts, strategic partnerships and multiple potential milestone payments tied to regulatory approvals and product sales, the company enters FY27 with improved financial capacity to pursue its growth objectives. Note- All data presented is based on information available at the time of writing.Disclaimer for Kapitales ResearchThe materials provided by Kapitales Research, including articles, news, data, reports, opinions, images, charts, and videos ("Content"), are intended for personal, non-commercial use only. The primary goal of this Content is to educate and inform readers. This Content is not meant to offer financial advice, nor does it include any recommendation or opinion that should be relied upon for making financial decisions. Certain Content on this platform may be sponsored or unsponsored, but it does not serve as a solicitation or endorsement to buy, sell, or hold any securities, nor does it encourage any specific investment activities. Kapitales Research is not authorized to provide investment advice, and we strongly advise users to seek guidance from a qualified financial professional, such as a financial advisor or stockbroker, before making any investment choices. Kapitales Research disclaims all liability for any direct, indirect, incidental, or consequential damages arising from the use of the Content, which is provided without any warranties. The opinions expressed by contributors or guests are their own and do not necessarily reflect the views of Kapitales Research. Media such as images or music used on this platform are either owned by Kapitales Research, sourced through paid subscriptions, or believed to be in the public domain. We have made reasonable efforts to credit sources where appropriate. Kapitales Research does not claim ownership of any third-party media unless explicitly stated otherwise. 

Customer Notice:Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.Disclosure: The information mentioned above has been sourced from the company reports and a third-party database, i.e. Koyfin. Investors are advised to use strict stop-loss to protect their investments in case of any unfavorable/uncertain market events. Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au